Literature DB >> 23933365

Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants?

Nicoline A T van der Maas1, Frits R Mooi, Sabine C de Greeff, Guy A M Berbers, Marina A E Conyn-van Spaendonck, Hester E de Melker.   

Abstract

BACKGROUND: Pertussis has resurged in the Netherlands since 1996. Several measures, i.e. acceleration of the schedule, introduction of a preschool acellular pertussis booster and change from an infant whole cell to an acellular pertussis combination vaccine were implemented in the National Immunisation Programme to decrease disease burden, in particular among very young infants who have the highest morbidity and mortality of pertussis. Nevertheless, a large outbreak occurred in 2011-2012.
METHODS: 1996-2010 was divided in 3-year-periods to assess the impact of the measures taken, using notifications and hospitalisations. These results were compared with 2011-2012. Mean Incidence rates (IRs) per 100,000 were calculated.
RESULTS: Although the measures taken resulted in decreased IRs among the targeted age groups after implementation, overall mean IRs of notifications increased from 32 (1996-2004) to 37 (2005-2010) and 63 (2011-2012). Young infants, not yet vaccinated, did not benefit; during the 2011-2012 outbreak, IR in 0-2-month-olds amounted to 259.6. IR among persons over 9 years of age increased from 6.8 (1996-1999) to 59.1 (2011-2012) For hospitalisations overall mean IRs decreased from 1.95 per 100,000 (1997-2004) to 0.88 (2005-2010) and 0.76 (2011).
CONCLUSION: The measures taken reduced IRs of notifications and hospitalisations among groups eligible for vaccination, but had no effect on the increasing IRs in adolescents and adults. This trend is also observed in other countries. The high IRs in 2012 in adolescents and adults probably resulted in increased transmission to infants, who are at risk for contracting severe pertussis. Therefore, additional measures to protect this group should be considered.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adults; Incidence; Infants; Pertussis; Vaccination; Vaccine effectiveness; Whooping cough

Mesh:

Substances:

Year:  2013        PMID: 23933365     DOI: 10.1016/j.vaccine.2013.07.060

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  34 in total

Review 1.  The pertussis enigma: reconciling epidemiology, immunology and evolution.

Authors:  Matthieu Domenech de Cellès; Felicia M G Magpantay; Aaron A King; Pejman Rohani
Journal:  Proc Biol Sci       Date:  2016-01-13       Impact factor: 5.349

2.  Greater Differentiation Would Have Been Desirable.

Authors:  Martin Hirte
Journal:  Dtsch Arztebl Int       Date:  2015-06-05       Impact factor: 5.594

3.  Dutch national immunization schedule: compliance and associated characteristics for the primary series.

Authors:  Elsemieke D Scheepers; Alies van Lier; Ingrid H Drijfhout; Guy Berbers; Nicoline A T van der Maas; Hester E de Melker; Mirjam J Knol
Journal:  Eur J Pediatr       Date:  2017-04-20       Impact factor: 3.183

4.  Identification of pertussis-specific effector memory T cells in preschool children.

Authors:  Lia de Rond; Rose-Minke Schure; Kemal Öztürk; Guy Berbers; Elisabeth Sanders; Inonge van Twillert; Maria Carollo; Françoise Mascart; Clara M Ausiello; Cecile A C M van Els; Kaat Smits; Anne-Marie Buisman
Journal:  Clin Vaccine Immunol       Date:  2015-03-18

5.  Reduced Bordetella pertussis-specific CD4+ T-Cell Responses at Older Age.

Authors:  Eleonora E Lambert; Inonge van Twillert; Lisa Beckers; Martien C M Poelen; Wanda G H Han; Daan K J Pieren; Cécile A C M van Els
Journal:  Front Aging       Date:  2022-02-02

Review 6.  Pertussis.

Authors:  Giovanni Gabutti; Chiara Azzari; Paolo Bonanni; Rosa Prato; Alberto E Tozzi; Alessandro Zanetti; Gianvincenzo Zuccotti
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 7.  Pertussis: Microbiology, Disease, Treatment, and Prevention.

Authors:  Paul E Kilgore; Abdulbaset M Salim; Marcus J Zervos; Heinz-Josef Schmitt
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

8.  Quantifying the impact of mass vaccination programmes on notified cases in the Netherlands.

Authors:  M van Wijhe; A D Tulen; H Korthals Altes; S A McDonald; H E de Melker; M J Postma; J Wallinga
Journal:  Epidemiol Infect       Date:  2018-03-14       Impact factor: 4.434

9.  Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012.

Authors:  M van Gent; C J Heuvelman; H G van der Heide; H O Hallander; A Advani; N Guiso; C H Wirsing von Kőnig; D F Vestrheim; T Dalby; N K Fry; D Pierard; L Detemmerman; J Zavadilova; K Fabianova; C Logan; A Habington; M Byrne; A Lutyńska; E Mosiej; C Pelaz; K Gröndahl-Yli-Hannuksela; A M Barkoff; J Mertsola; A Economopoulou; Q He; F R Mooi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-20       Impact factor: 3.267

10.  Genetic Variation of Bordetella pertussis in Austria.

Authors:  Birgit Wagner; Helen Melzer; Georg Freymüller; Sabine Stumvoll; Pamela Rendi-Wagner; Maria Paulke-Korinek; Andreas Repa; Frits R Mooi; Herwig Kollaritsch; Helmut Mittermayer; Harald H Kessler; Gerold Stanek; Ralf Steinborn; Michael Duchêne; Ursula Wiedermann
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.